Antihypertensive Drugs Market (Drug: Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers, and Others; Condition: Primary Hypertension and Secondary Hypertension; Medication Type: Monotherapy, Combination Therapy, and Fixed Dose Combinations; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Rising Global Burden of Hypertension Provides Impetus for Development of New Drugs

Hypertension is a critical health condition that can lead to cardiovascular diseases, renal failure, stroke, and even death. According to the World Health Organization, 1.13 billion individuals worldwide had hypertension in 2018, of which two-third resided in low income and developing countries. Over the past decade, the global burden of hypertension has increased, primarily driven by a significant rise in population, lifestyle changes, and increase in the geriatric population worldwide. In the current scenario, hypertension is effectively controlled in less than 20% of the patients across the world, which means there is a mounting demand for antihypertensive drugs, particularly in developing regions.

Over the past few decades, a significant amount of research has been undertaken for the discovery of new, effective, and novel antihypertensive drugs. Despite significant advancements in genomics, clinical applications of these relatively recent developments in the antihypertensive drugs market landscape remain far-fetched. Drug manufacturers continue to invest significant resources toward the discovery of blockbuster antihypertensive drugs. However, to achieve this goal, stakeholders in the current antihypertensive drugs market are likely to adopt a cross-sector approach that will focus on several areas, including data, digital, population sciences, etc.

The global antihypertensive drugs market is expected to reach a market value of ~US$ 33.9 Bn by the end of 2027.

Adoption of Combination Therapies to Gain Significant Momentum

Research and development have taken the center stage in the current antihypertensive drugs market. Established and upcoming players in the current market landscape are increasingly focusing on the formulation of effective combination therapies. Uptake of combination therapies is a trend that is projected to gain significant momentum during the forecast period (2019-2027).

Focus on combination therapies in the antihypertensive drugs market is likely to increase to achieve therapeutic goals. Furthermore, recent guidelines related to hypertension management suggest that combination therapy, in which two or more drugs are combined, is ideal for patients that have systolic blood pressure and patients at a higher cardiovascular risk. In addition, several research activities have revealed that ~25% of patients may require a combination therapy of three antihypertensive drugs to attain the desirable outcome. Combination therapy is expected to be the most prominent medication type. The combination therapy segment of the antihypertensive drugs market is projected to reach a market value of ~ US$ 12.4 Mn and account for a market share of ~43% in 2020.

Get a glimpse of the in-depth analysis through our Report Brochure

Conventionally, a higher dose of monotherapy is required. However, this approach could potentially increase the risk of side effects. These drawbacks of monotherapy have paved the way for other medication types in the global antihypertensive drugs market such as fixed dose combinations and combination therapy. With a market share of ~33%, the fixed dose combinations medication type segment is expected to hold the second-highest market share of the antihypertensive drugs market in 2020.

Companies Focus on R&D to Offer Effective Antihypertensive Drugs

Stakeholders in the global antihypertensive drug market are increasing their efforts toward the discovery of new drugs to manage high blood pressure. Research activities are focused on the discovery of new combination drugs. For instance, clinical trials have revealed that new combination therapy could revolutionize hypertension management worldwide. A team of researchers from the George Institute for Global Health tested the efficacy and safety of an innovative combination drug to deal with hypertension and elevated blood pressure. The new drug, which was declared safe after a series of clinical trials, is a combination of three drugs - amlodipine, chlorthalidone, and telmisartan. Several other drug manufacturers are focused on receiving approval from the FDA for hypertension medicine. For instance, in December 2018, Alembic Pharmaceuticals announced that the company received approval from the US FDA for a new hypertension medicine.

Hospital pharmacies are expected to be the most sought-after distribution channel. Additionally, ~44% of the total sales of antihypertensive drugs is expected to take place from hospital pharmacies in 2020. Hospital pharmacies segment is projected to generate a revenue of ~US$ 12.5 Bn in 2020.

Analysts’ Viewpoint

The global antihypertensive drugs market is projected to expand at a CAGR of ~2% during the forecast period. Despite apprehensions among drug manufacturers about the development of new antihypertensive drugs, research and activities are likely to concentrate on improving the effectiveness of combination therapies. The adoption of combination therapies will be the highest, followed by fixed dose combinations. Players operating in the antihypertensive drugs market should focus on the development of cost-effective combination therapies. North America and Europe are expected to be the major regions, in terms of innovations and new drug development, owing to high concentration of top tier market players.  

Antihypertensive Drugs Market: Overview

This report analyzes the current scenario and future prospects of the global antihypertensive drugs market. Rise in prevalence of geriatric population is expected to increase at a rapid pace in the next few years. Based on United Nations Report 2017, the geriatric population aged 60 years and above is expected to double by 2050. The number is anticipated to increase from 962 million in 2017 to 2.1 billion by 2050.

Moreover, the geriatric patient pool in developing regions such as Latin America, Asia, and Africa is likely to increase rapidly. Age is a primary risk factor for hypertension. Prevalence of hypertension is comparatively high in the elderly population; approximately 70% of high blood pressure patients are over 60. Additionally, aging increases blood pressure, as elasticity of the arterial system is reduced. All these factors are expected to drive the antihypertensive drugs market in the next few years.

The report provides an elaborate executive summary, which provides a snapshot of various segments of the antihypertensive drugs market. It also provides information and data analysis of the global antihypertensive drugs market with regards to segments based on therapy type, type, medication type, distribution channel, and region.

The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global antihypertensive drugs market

The report includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the antihypertensive drugs market

The report on the global antihypertensive drugs market offers market attractiveness analysis of regions and segments

The last section of the report comprises quantitative and qualitative analysis on market share/position of key players operating in the global antihypertensive drugs market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global antihypertensive drugs market. 

Antihypertensive Drugs Market: Key Segments

In terms of drug, the antihypertensive drugs market has been segmented into diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, vasodilators, calcium channel blockers, renin inhibitors, alpha-blockers, and others. The diuretics segment has been sub-segmented into thiazide diuretic, loop diuretics, and potassium-sparing diuretics. Beta-blockers segment has been sub-segmented into beta-1 selective and intrinsic sympathomimetic.

The angiotensin receptor blockers segment held a major share of the global antihypertensive drugs market in 2018 and the trend is expected to continue during the forecast period

Based on condition, the antihypertensive drugs market has been segregated into primary hypertension and secondary hypertension. The primary hypertension segment accounted for a major market share in 2018; the trend is expected to continue during the forecast period.

In terms of medication type, the antihypertensive drugs market has been categorized into monotherapy, combination therapy, and fixed dose combinations

Based on distribution channel, the global antihypertensive drugs market has been classified into retail pharmacies, hospital pharmacies, online pharmacies, and others. The hospital pharmacies segment of accounted for a major share of the antihypertensive drugs market in 2018.

Market size and forecast for each of these segments have been provided from 2017 to 2027. The CAGR of respective segment has also been provided from 2019 to 2027, considering 2018 as the base year. 

Antihypertensive Drugs Market: Regional Outlook

In terms of region, the global antihypertensive drugs market has been divided into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been further divided into countries/sub-regions.

The antihypertensive drugs market report provides size and forecast for each region and country/sub-region from 2017 to 2027. The CAGR for each of these regions and countries have also been provided for the forecast period from 2019 to 2027. The antihypertensive drugs market study also covers the competitive scenario in these regions. 

Companies Covered in Antihypertensive Drugs Market Report

Key players in the global antihypertensive drugs market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies

Major companies profiled in the global antihypertensive drugs market report include

• Pfizer, Inc.
• Sanofi S.A.
• Novartis AG
• AstraZeneca plc
• Boehringer Ingelheim GmbH

Key Questions Answered in Antihypertensive Drugs Market Report

• What are the major drivers, restraints, and opportunities in the market?
• What will be the revenue share projections of key segments in the antihypertensive drugs market during the forecast period?
• Which segment is likely to lead the antihypertensive drugs market in terms of revenue by 2027?
• How mergers & acquisitions among players are widening the scope for antihypertensive drugs market?
• What are the market positions of different companies operating in the global antihypertensive drugs market?

Antihypertensive Drugs Market – Segmentation

Drug

• Diuretics
• Thiazide Diuretics
• Loop Diuretics
• Potassium-sparing Diuretics
• Angiotensin Converting Enzyme Inhibitors
• Angiotensin Receptor Blockers
• Beta-blockers
• Beta-1 Selective
• Intrinsic Sympathomimetic
• Vasodilators
• Calcium Channel Blockers
• Renin Inhibitors
• Alpha-blockers
• Others

Condition

• Primary Hypertension
• Secondary Hypertension

Medication Type

• Monotherapy
• Combination Therapy
• Fixed Dose Combinations

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Others

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface 

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Antihypertensive Drugs Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Key Industry Developments 

    5.2. Regulatory Scenario

    5.3. Reimbursement Scenario

    5.4. Key Mergers & Acquisitions

    5.5. Technological Advancements

6. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug 

    6.1. Introduction & Definition 

    6.2. Global Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2030

        6.2.1. Diuretics

            6.2.1.1. Thiazide Diuretics

            6.2.1.2. Loop Diuretics

            6.2.1.3. Potassium-sparing Diuretics

        6.2.2. Angiotensin Converting Enzyme Inhibitors

        6.2.3. Angiotensin Receptor Blockers

        6.2.4. Beta-blockers

            6.2.4.1. Beta-1 Selective

            6.2.4.2. Intrinsic Sympathomimetic

        6.2.5. Vasodilators

        6.2.6. Calcium Channel Blockers

        6.2.7. Renin Inhibitors

        6.2.8. Alpha-blockers

        6.2.9. Others

    6.3. Global Antihypertensive Drugs Market Attractiveness, by Drug

7. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition

    7.1. Introduction & Definition 

    7.2. Global Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2030

        7.2.1. Primary Hypertension

        7.2.2. Secondary Hypertension

    7.3. Global Antihypertensive Drugs Market Attractiveness, by Condition

8. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type 

    8.1. Introduction 

    8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2030

        8.2.1. Monotherapy

        8.2.2. Combination Therapy

        8.2.3. Fixed Dose Combinations

    8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type

9. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel

    9.1. Introduction 

    9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2030

        9.2.1. Retail Pharmacies

        9.2.2. Hospital Pharmacies 

        9.2.3. Online Pharmacies

        9.2.4. Others

    9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel

10. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Region

    10.1. Introduction 

    10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017–2030

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa  

    10.3. Global Antihypertensive Drugs Market Attractiveness, by Region

11. North America Antihypertensive Drugs Market Analysis and Forecast 

    11.1. Introduction

    11.2. North America Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2030

        11.2.1. Diuretics

            11.2.1.1. Thiazide Diuretics

            11.2.1.2. Loop Diuretics

            11.2.1.3. Potassium-sparing Diuretics

        11.2.2. Angiotensin Converting Enzyme Inhibitors

        11.2.3. Angiotensin Receptor Blockers

        11.2.4. Beta-blockers

            11.2.4.1. Beta-1 Selective

            11.2.4.2. Intrinsic Sympathomimetic

        11.2.5. Vasodilators

        11.2.6. Calcium Channel Blockers

        11.2.7. Renin Inhibitors

        11.2.8. Alpha-blockers

        11.2.9. Others

    11.3. North America Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2030

        11.3.1. Primary Hypertension

        11.3.2. Secondary Hypertension

    11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2030

        11.4.1. Monotherapy

        11.4.2. Combination Therapy

        11.4.3. Fixed Dose Combinations

        11.4.4. Others

    11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2030

        11.5.1. Retail Pharmacies

        11.5.2. Hospital Pharmacies 

        11.5.3. Online Pharmacies

        11.5.4. Others

    11.6. North America Antihypertensive Drugs Market Value Forecast, by Country, 2017–2030

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Antihypertensive Drugs Market Attractiveness Analysis

        11.7.1. By Drug

        11.7.2. By Condition

        11.7.3. By Medication Type

        11.7.4. By Distribution Channel

        11.7.5. By Country

12. Europe Antihypertensive Drugs Market Analysis and Forecast 

    12.1. Introduction

    12.2. Europe Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2030

        12.2.1. Diuretics

            12.2.1.1. Thiazide Diuretics

            12.2.1.2. Loop Diuretics

            12.2.1.3. Potassium-sparing Diuretics

        12.2.2. Angiotensin Converting Enzyme Inhibitors

        12.2.3. Angiotensin Receptor Blockers

        12.2.4. Beta-blockers

            12.2.4.1. Beta-1 Selective

            12.2.4.2. Intrinsic Sympathomimetic

        12.2.5. Vasodilators

        12.2.6. Calcium Channel Blockers

        12.2.7. Renin Inhibitors

        12.2.8. Alpha-blockers

        12.2.9. Others

    12.3. Europe Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2030

        12.3.1. Primary Hypertension

        12.3.2. Secondary Hypertension

    12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2030

        12.4.1. Monotherapy

        12.4.2. Combination Therapy

        12.4.3. Fixed Dose Combinations

        12.4.4. Others

    12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2030

        12.5.1. Retail Pharmacies

        12.5.2. Hospital Pharmacies 

        12.5.3. Online Pharmacies

        12.5.4. Others

    12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2030

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy 

        12.6.6. Rest of Europe

    12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis

        12.7.1. By Drug

        12.7.2. By Condition 

        12.7.3. By Medication Type

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast 

    13.1. Introduction

    13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2030

        13.2.1. Diuretics

            13.2.1.1. Thiazide Diuretics

            13.2.1.2. Loop Diuretics

            13.2.1.3. Potassium-sparing Diuretics

        13.2.2. Angiotensin Converting Enzyme Inhibitors

        13.2.3. Angiotensin Receptor Blockers

        13.2.4. Beta-blockers

            13.2.4.1. Beta-1 Selective

            13.2.4.2. Intrinsic Sympathomimetic

        13.2.5. Vasodilators

        13.2.6. Calcium Channel Blockers

        13.2.7. Renin Inhibitors

        13.2.8. Alpha-blockers

        13.2.9. Others

    13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2030

        13.3.1. Primary Hypertension

        13.3.2. Secondary Hypertension

    13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2030

        13.4.1. Monotherapy

        13.4.2. Combination Therapy

        13.4.3. Fixed Dose Combinations

        13.4.4. Others

    13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2030

        13.5.1. Retail Pharmacies

        13.5.2. Hospital Pharmacies 

        13.5.3. Online Pharmacies

        13.5.4. Others

    13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2030

        13.6.1. Japan

        13.6.2. China

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis

        13.7.1. By Drug

        13.7.2. By Condition

        13.7.3. By Medication Type

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region

14. Latin America Antihypertensive Drugs Market Analysis and Forecast 

    14.1. Introduction

    14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2030

        14.2.1. Diuretics

            14.2.1.1. Thiazide Diuretics

            14.2.1.2. Loop Diuretics

            14.2.1.3. Potassium-sparing Diuretics

        14.2.2. Angiotensin Converting Enzyme Inhibitors

        14.2.3. Angiotensin Receptor Blockers

        14.2.4. Beta-blockers

            14.2.4.1. Beta-1 Selective

            14.2.4.2. Intrinsic Sympathomimetic

        14.2.5. Vasodilators

        14.2.6. Calcium Channel Blockers

        14.2.7. Renin Inhibitors

        14.2.8. Alpha-blockers

        14.2.9. Others

    14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2030

        14.3.1. Primary Hypertension

        14.3.2. Secondary Hypertension

    14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2030

        14.4.1. Monotherapy

        14.4.2. Combination Therapy

        14.4.3. Fixed Dose Combinations

        14.4.4. Others

    14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2030

        14.5.1. Retail Pharmacies

        14.5.2. Hospital Pharmacies 

        14.5.3. Online Pharmacies

        14.5.4. Others 

    14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2030

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Antihypertensive Drugs Market Attractiveness Analysis

        14.7.1. By Drug

        14.7.2. By Condition

        14.7.3. By Medication Type

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region

15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast 

    15.1. Introduction

    15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2030

        15.2.1. Diuretics

            15.2.1.1. Thiazide Diuretics

            15.2.1.2. Loop Diuretics

            15.2.1.3. Potassium-sparing Diuretics

        15.2.2. Angiotensin Converting Enzyme Inhibitors

        15.2.3. Angiotensin Receptor Blockers

        15.2.4. Beta-blockers

            15.2.4.1. Beta-1 Selective

            15.2.4.2. Intrinsic Sympathomimetic

        15.2.5. Vasodilators

        15.2.6. Calcium Channel Blockers

        15.2.7. Renin Inhibitors

        15.2.8. Alpha-blockers

        15.2.9. Others

    15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2030

        15.3.1. Primary Hypertension

        15.3.2. Secondary Hypertension

    15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2030

        15.4.1. Monotherapy

        15.4.2. Combination Therapy

        15.4.3. Fixed Dose Combinations

        15.4.4. Others

    15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2030

        15.5.1. Retail Pharmacies

        15.5.2. Hospital Pharmacies 

        15.5.3. Online Pharmacies

        15.5.4. Others 

    15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2030

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Israel

        15.6.4. Rest of Middle East & Africa

    15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis

        15.7.1. By Drug

        15.7.2. By Condition

        15.7.3. By Medication Type

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Global Antihypertensive Drugs Market Share Analysis, by Company (2018)

    16.2.  Company Profiles

        16.2.1. Pfizer Inc.

            16.2.1.1. Company Description

            16.2.1.2. Business Overview

            16.2.1.3. Financial Overview

            16.2.1.4. Strategic Overview

            16.2.1.5. SWOT Analysis

        16.2.2. Sanofi S.A

            16.2.2.1. Company Description

            16.2.2.2. Business Overview

            16.2.2.3. Financial Overview

            16.2.2.4. Strategic Overview

            16.2.2.5. SWOT Analysis

        16.2.3. Novartis AG

            16.2.3.1. Company Description

            16.2.3.2. Business Overview

            16.2.3.3. Financial Overview

            16.2.3.4. Strategic Overview

            16.2.3.5. SWOT Analysis

        16.2.4. Boehringer Ingelheim GmbH

            16.2.4.1. Company Description

            16.2.4.2. Business Overview

            16.2.4.3. Financial Overview

            16.2.4.4. Strategic Overview

            16.2.4.5. SWOT Analysis

        16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)

            16.2.5.1. Company Description

            16.2.5.2. Business Overview

            16.2.5.3. Financial Overview

            16.2.5.4. Strategic Overview

            16.2.5.5. SWOT Analysis

        16.2.6. F. Hoffmann-La Roche Ltd.

            16.2.6.1. Company Description

            16.2.6.2. Business Overview

            16.2.6.3. Financial Overview

            16.2.6.4. Strategic Overview

            16.2.6.5. SWOT Analysis

        16.2.7. Bayer AG

            16.2.7.1. Company Description

            16.2.7.2. Business Overview

            16.2.7.3. Financial Overview

            16.2.7.4. Strategic Overview

            16.2.7.5. SWOT Analysis

        16.2.8. Daiichi Sankyo Company, Limited

            16.2.8.1. Company Description

            16.2.8.2. Business Overview

            16.2.8.3. Financial Overview

            16.2.8.4. Strategic Overview

            16.2.8.5. SWOT Analysis

        16.2.9. Takeda Pharmaceutical Company Limited

            16.2.9.1. Company Description

            16.2.9.2. Business Overview

            16.2.9.3. Financial Overview

            16.2.9.4. Strategic Overview

            16.2.9.5. SWOT Analysis